Reflecting on this year's PHA conference in Dallas, columnist Mike Naple writes that connecting with community can be the best medicine.

Most PAH patients who completed one year in a CS1 expanded access program had stable or improved clinical measures.

Nine members of the pulmonary hypertension (PH) community have received awards for their support of the Pulmonary ...

Blocking a signaling pathway in certain white blood cells may prevent clots from obstructing blood flow and causing CTEPH, per a new study.

At the Pulmonary Hypertension Association’s (PHA) biannual conference, it is easy to feel like you should be able to do more. There are sessions to attend, people to meet, dinners to join, and ...

Corsair Pharma‘s experimental skin-worn patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly ...

Subtle liver problems may contribute to the development of pulmonary arterial hypertension (PAH), suggesting complex communication between the lungs and liver along a so-called lung-liver axis, ...

Oxiwear‘s wearable medical device, which continuously tracks oxygen levels in people with pulmonary hypertension (PH) and other heart or lung conditions, will now be covered by Medicare and certain ...

Enrollment is complete in the Phase 2 APEX trial of TX45, Tectonic Therapeutic‘s experimental drug for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), ...

A gene called NDRG1 may help drive blood vessel remodeling seen in chronic thromboembolic pulmonary hypertension (CTEPH) by shifting smooth muscle cells toward a scar-forming state, a study found.